Shots:

• The P-III CheckMate -743 trial evaluates Opdivo (3mg/kg- q2w) + Yervoy (1mg/kg- q6w) vs CT in 605 patients with previously untreated unresectable MPM. The results will be presented at ESMO 2021
• The result showed an improvement in OS with a reduction in risk of death- patients were alive (23% vs 15%) @3yrs.- improvement in m-OS (18.1 vs 14.1mos.)- ORR (39.6% vs 44.0%)- patients responded (28% vs 0%)- m-DOR (11.6 vs 6.7mos.). The safety profile was consistent with previous data & no new safety signals were observed
• The combination has been approved for unresectable MPM in 14 countries globally including the US- EU- Japan & China while other regulatory applications are under review globally

  Ref: BMS | Image: BMS